Physician profile
Joseph Bui
NPI 1194469130
$5,490.20
in general payments reported to CMS, 2019-2025
22 companies · $2,578 in 2025
The $2,578 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $310 · 2023: $1,029 · 2024: $1,573 · 2025: $2,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,178 · Travel and Lodging: $2.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,177.82 |
| Travel and Lodging | $2.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,953.95 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $627.15 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $553.93 | 2023-2025 | Auvelity, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $544.49 | 2022-2025 | Caplyta |
| Alkermes, INC. | $537.15 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Lilly USA, LLC | $336.48 | 2022-2025 | Mounjaro, Kisunla |
| Vanda Pharmaceuticals INC. | $203.69 | 2024-2025 | Fanapt, Hetlioz |
| Phathom Pharmaceuticals, INC. | $166.49 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $110.86 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $62.65 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $61.75 | 2022-2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $57.80 | 2022-2025 | Rexulti |
| Edwards Lifesciences Corporation | $54.14 | 2023 | |
| Tris Pharma INC | $49.07 | 2024-2025 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $37.80 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $30.27 | 2025 | Veozah |
| Verity Pharmaceuticals INC. | $21.56 | 2025 | Tlando |
| Eisai INC. | $19.14 | 2025 | |
| Impel Pharmaceuticals INC. | $17.95 | 2023 | Trudhesa |
| Azurity Pharmaceuticals, INC. | $16.40 | 2025 | Azmiro |
| Hologic Sales and Service, LLC | $14.07 | 2024 | Aptima |
| Novo Nordisk INC | $13.41 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.